Abeona Therapeutics Inc. (NASDAQ:ABEO)’s share price fell 4.5% on Thursday . The stock traded as low as $3.58 and last traded at $3.59, with a volume of 54,854 shares changing hands. The stock had previously closed at $3.76.

Several research firms have recently weighed in on ABEO. Zacks Investment Research upgraded Abeona Therapeutics from a “hold” rating to a “buy” rating and set a $3.00 target price on the stock in a research report on Wednesday, April 27th. FBR & Co reaffirmed a “buy” rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Sunday, May 22nd. Maxim Group reaffirmed a “buy” rating and issued a $6.00 price target on shares of Abeona Therapeutics in a report on Tuesday, May 17th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and issued a $17.00 price target on shares of Abeona Therapeutics in a report on Wednesday, May 18th.

The company’s 50 day moving average is $2.71 and its 200-day moving average is $2.68. The company’s market capitalization is $118.39 million.

Abeona Therapeutics (NASDAQ:ABEO) last released its earnings results on Monday, May 16th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.04. Equities analysts forecast that Abeona Therapeutics Inc. will post ($0.66) EPS for the current year.

A hedge fund recently raised its stake in Abeona Therapeutics stock. Royce & Associates LLC raised its stake in Abeona Therapeutics Inc. (NASDAQ:ABEO) by 424.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 299,643 shares of the biopharmaceutical company’s stock after buying an additional 242,462 shares during the period. Royce & Associates LLC owned about 0.92% of Abeona Therapeutics worth $1,007,000 as of its most recent filing with the SEC.

Abeona Therapeutics, Inc develops and delivers gene therapy and plasma-based products for rare diseases. The Company’s programs include AB0-101 (AAV9 NAGLU) and ABO-102 (scAAV9 SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). It is developing ABO-201 (scAAV9 CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV LK19 FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.